Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.62 |
| ▸ | PARP1 | P09874 | 9/20 | 0.56 |
| ▸ | IP6K1 | Q92551 | 6/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.53 |
| ▸ | PIM1 | P11309 | 2/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.51 |
| ▸ | TUBB | P07437 | 1/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11117461 | 0.84 | PARP1 (0.58) | SLC2A1PARP1IP6K1CHEK1PIM1 | |
| SCHEMBL1257333 | 0.81 | PARP1 (0.63) | SLC2A1PARP1IP6K1CHEK1PIM1 | |
| SCHEMBL2017082 | 0.80 | MMP12 (0.63) | SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL1998529 | 0.79 | SLC2A1 (0.54) | SLC2A1PARP1IP6K1CHEK1PIM1 | |
| SCHEMBL19373198 | 0.78 | IP6K1 (0.61) | SLC2A1PARP1IP6K1CHEK1PIM1 | |
| SCHEMBL6824901 | 0.78 | PARP1 (0.54) | SLC2A1PARP1IP6K1CHEK1PIM1 | |
| SCHEMBL1875326 | 0.77 | MMP12 (0.46) | SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL11135261 | 0.77 | IP6K1 (0.63) | SLC2A1PARP1IP6K1CHEK1PIM1 | |
| SCHEMBL8304643 | 0.77 | HTR1D (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27576840 | 0.75 | SLC2A1 (0.50) | SLC2A1PARP1IP6K1CHEK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111247152-B | Cyclic iminopyrimidine derivatives as kinase inhibitors | 璧辰医药技术股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11932647-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | ABM THERAPEUTICS CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3684772-B1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS CORP (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230331682-A1 | NEW QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331682-A1 | NEW QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20220251089-A1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS CORPORATION (CA) | 2022-08-11 | — | — | US | disclosed |
| WO-2022129259-A1 | NEW QUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-23 | — | — | WO | disclosed |
| US-11254680-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | ABM THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254680-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | ABM THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
| US-11225485-B2 | — | — | 2022-01-18 | — | — | US | disclosed |
| WO-2008033748-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| CN-1882573-A | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331682-A1 | NEW QUINAZOLINONE DERIVATIVES | NDUFS3, NQO2, NDUFC1 | SLC2A1 4378/4885PARP1 1198/4885IP6K1 3059/4885 |
| US-11225485-B2 | — | BRAF, RAF1, CDK4 | SLC2A1 2793/4885PARP1 299/4885IP6K1 321/4885 |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | SLC2A1 1535/4885PARP1 2499/4885IP6K1 850/4885 |
| US-20220251089-A1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | BRAF, CDK4, RAF1 | SLC2A1 2102/4885PARP1 276/4885IP6K1 130/4885 |
| US-11254680-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | BRAF, CDK4, RAF1 | SLC2A1 2102/4885PARP1 276/4885IP6K1 130/4885 |
| US-11932647-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | BRAF, CDK4, RAF1 | SLC2A1 2102/4885PARP1 276/4885IP6K1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.